Understanding the genetic makeup of neuroblastic tumors and their impact on treatment outcomes
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
This study is trying to see how the genetic features of neuroblastic tumors affect how aggressive they are and how well different treatments work for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2070 (estimated) |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | naxitamab |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT00588068 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the genetic and biochemical characteristics of neuroblastic tumors to determine how these factors influence tumor aggressiveness and treatment options. It involves collecting tumor and marrow specimens, as well as blood samples, to study the molecular-genetic makeup of the tumors and correlate these findings with clinical outcomes. The research will also explore the signaling pathways of neuroblastic tumors in relation to embryonic neuroectodermal cells, providing insights into potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with neuroblastic tumors or those with clinically suspected neuroblastic tumors.
Not a fit: Patients without neuroblastic tumors or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with neuroblastoma.
How similar studies have performed: Other studies focusing on the molecular characterization of tumors have shown promise in improving treatment outcomes, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System OR * Clinically suspected neuroblastic tumors. PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY): PK Draw Inclusion Criteria * Patients who receive naxitamab as part of their standard of care Exclusion Criteria: * None
Where this trial is running
New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Nai-Kong Cheung, M.D., Ph.D. — Memorial Sloan Kettering Cancer Center
- Study coordinator: Nai-Kong Cheung, M.D., Ph.D.
- Phone: 646-888-2313
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.